Form 4: Allogene CFO Sells Shares for Tax Obligations

Allogene Therapeutics' CFO, Geoffrey M. Parker, sold 36,744 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Geoffrey M. Parker, Chief Financial Officer of Allogene Therapeutics, Inc. (ALLO), reported a transaction involving the company's common stock.
• On October 21, 2025, Mr. Parker disposed of 36,744 shares of common stock at a price of $1.2565 per share.
• This sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plan to satisfy tax withholding obligations upon the vesting of restricted stock units, and was not a discretionary trade.
• Following this transaction, Mr. Parker beneficially owns 1,276,796 shares of Allogene Therapeutics common stock.
• His beneficial ownership also includes 6,000 shares acquired on March 14, 2025, and another 6,000 shares acquired on September 15, 2025, both through an employee stock purchase program.

Sentiment

Score: 7

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax obligations, which is a common occurrence for executives with equity compensation. The CFO continues to hold a substantial number of shares and has also acquired shares through an ESPP, indicating continued alignment with the company.

Positives

• The sale of shares was non-discretionary, solely to cover tax withholding obligations related to restricted stock unit vesting, rather than a voluntary divestment.
• The Chief Financial Officer continues to hold a significant number of shares (1,276,796) after the transaction, indicating continued alignment with shareholder interests.
• The reporting person acquired 12,000 shares through an employee stock purchase program in March and September 2025, demonstrating ongoing participation in the company's equity plans.

Negatives

• The Chief Financial Officer's direct beneficial ownership of common stock decreased by 36,744 shares.

Future Outlook

NA

Management Comments

• The sale represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.

Industry Context

NA

Stakeholder Impact

• Shareholders: The non-discretionary nature of the sale mitigates negative sentiment often associated with insider selling. The CFO's continued significant ownership (1,276,796 shares) suggests ongoing alignment with shareholder interests.
• Employees: The mention of an Employee Stock Purchase Program (ESPP) highlights a benefit available to employees, fostering alignment and participation in the company's equity.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by the CFO to meet tax obligations on vested restricted stock units. Such transactions are common and do not typically signal a change in management's outlook or a lack of confidence in the company. The CFO still retains a significant stake in the company and has also acquired shares through an employee stock purchase program, suggesting continued alignment with shareholder interests. Therefore, the filing itself does not provide a basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Allogene Therapeutics, ALLO, Form 4, insider trading, stock sale, CFO, Geoffrey Parker, restricted stock units, RSU, tax withholding, employee stock purchase program, ESPP